Results 131 to 140 of about 28,989 (238)
European Journal of Neurology, Volume 33, Issue 6, June 2026.ABSTRACT Background The F64L variant is among the most frequent TTR mutations in Italy, typically associated with a predominantly neurologic phenotype and limited cardiac involvement. Methods Data from 181 ATTRv patients in the multicenter Patisiranitaly database treated with Patisiran since 2020 were analyzed. Neurologic impairment scores, Norfolk QoL‐
Marco Ceccanti +53 more
wiley +1 more source
Journal of Medical Primatology, Volume 55, Issue 3, June 2026.ABSTRACT Background Thyroid disease is reported in orangutans, but to properly diagnose and manage these disorders, reference intervals for circulating thyroid hormones are needed. Methods Commercial immunoassay kits for total thyroxine (TT4) and free thyroxine (FT4) were validated for use in orangutans (Pongo spp.).
Melissa A. Fayette +4 more
wiley +1 more source
Journal of the Peripheral Nervous System, Volume 31, Issue 2, June 2026.ABSTRACT Diabetic peripheral neuropathy (DPN) is a prevalent and disabling complication of diabetes, yet whether established clinical DPN is reversible remains debated. At the 35th Annual Meeting of NEUROdiab, a formal debate examined arguments ‘for’ and ‘against’ the proposition that clinical DPN can be reversed.
Gordon Sloan +9 more
wiley +1 more source
Journal of the Peripheral Nervous System, Volume 31, Issue 2, June 2026.ABSTRACT Background and Aims Hereditary transthyretin amyloidosis (ATTRv) is a multisystemic disease where early neuropathy signs are challenging to detect conventionally. This study aimed to evaluate hand motor performance in ATTRv using the Hand Test System (HTS) across disease stages and examine correlations with standard measures.
Mehrnaz Hamedani +25 more
wiley +1 more source
The pathophysiology of variant transthyretin (TTR) amyloidosis (ATTRv) is associated with destabilizing mutations in the TTR tetramer. However, why TTR with a wild-type genetic sequence misfolds and aggregates in wild-type transthyretin amyloidosis ...
Shunsuke Watanabe +11 more
core +1 more source
Patient characteristics for men and women with transthyretin amyloidosis.
, 2015 Type A, mixture of intact and fragmented transthyretin; Type B, only full length transthyretin. Continuous data are presented as median (range) and categorical data are presented as counts and percentages. Statistically significant differences are marked
Per Westermark (79625) +4 more
core +1 more source
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
, 2013 BACKGROUND: Transthyretin amyloidosis is caused by the deposition of hepatocyte-derived transthyretin amyloid in peripheral nerves and the heart. A therapeutic approach mediated by RNA interference (RNAi) could reduce the production of transthyretin ...
Coelho, Teresa +30 more
core +1 more source
, 2023 Transthyretin amyloidosis is an increasingly recognised cause of cardiac amyloidosis and heart failure with preserved ejection fraction. Best clinical practice screens patients presenting with transthyretin amyloidosis to exclude transthyretin ...
Taylor, Mark Simon
core
Inhibition of Transthyretin Fibrillogenesis Using a Conformation Specific Antibody
, 2012 Immunoglobulin-mediated inhibition of amyloid fibril formation in vivo is a promising strategy for the treatment of protein misfolding diseases such as the amyloidoses.
Bugyei-Twum, Antoinette
core +1 more source